Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
about
Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
description
2016 nî lūn-bûn
@nan
2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@ast
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@en
type
label
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@ast
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@en
prefLabel
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@ast
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@en
P2860
P1476
Histone deacetylase inhibitor ...... culean cancer chemoresistance.
@en
P2093
Shabir Ahmad Ganai
P2860
P304
P356
10.3109/13880209.2015.1135966
P577
2016-02-05T00:00:00Z